• N&PD Moderators: Skorpio

calcitonin gene-related peptide receptor

Hammilton

Bluelighter
Joined
Sep 2, 2008
Messages
3,435
This is the target of Mercks new (terribly named) migraine drug telcagepants. Easy to remember the spelling for some reason...

Anyway, is the calcitonin gene-related peptide receptor a receptor with potential psychoactive effects? Telcagepants is an antagonist at this receptor, but what do agonists do? Hopefully it's not inducing migraines.

I haven't found the structure or IUPAC for telcagepants, lots of fluff about it, though.
 
Tel-cage-pants?! LOL!

Where did you take the info from? Certainly I could have a look for the structure, but don't expect too much. It's not unsual that compounds in the pipeline do not get revelead at an early stage of the process of approval...

- Murphy
 
Telcagepants is probably just a powerful vasodilator; i doubt the CGRP receptor is a target for psychoactive drugs. Anandamide does release CGRP, but CGRP is simply an ultra potent vasodilator. The other day I saw CGRP for sale at $750/mg, on a site selling peptides for bodybuilders...

The endogenous cannabinoid receptor agonist anandamide is a powerful vasodilator of isolated vascular preparations, but its mechanism of action is unclear. Here we show that the vasodilator response to anandamide in isolated arteries is capsaicin-sensitive and accompanied by release of calcitonin-gene-related peptide (CGRP). The selective CGRP-receptor antagonist 8-37 CGRP, but not the cannabinoid CB1 receptor blocker SR141716A, inhibited the vasodilator effect of anandamide. Other endogenous (2-arachidonylglycerol, palmitylethanolamide) and synthetic (HU 210, WIN 55,212-2, CP 55,940) CB1 and CB2 receptor agonists could not mimic the action of anandamide. The selective 'vanilloid receptor' antagonist capsazepine inhibited anandamide-induced vasodilation and release of CGRP. In patch-clamp experiments on cells expressing the cloned vanilloid receptor (VR1), anandamide induced a capsazepine-sensitive current in whole cells and isolated membrane patches. Our results indicate that anandamide induces vasodilation by activating vanilloid receptors on perivascular sensory nerves and causing release of CGRP. The vanilloid receptor may thus be another molecular target for endogenous anandamide, besides cannabinoid receptors, in the nervous and cardiovascular systems.
 
Yea that name fucking sucks. Jeez... well without saying too much, we're currently partnered with Merck and will have a few things gear up for human trials soon. I hope they don't botch up the naming... hopefully our boss will step in with quality suggestions/make them not do stuff that sucks.

Peptides kick ass by the way. My name hints at a possible future area of research...... ;P
 
Hm, so I read, I have long been interested in dermorphin, from Phyllomedusa frogs, and as for the name, sheesh, what are those pharmacologists smoking when they come up with names like that.

Whatever it is, I want some.
 
Maybe it's got a really weird pronunciation that y'all aren't seeing. Like... tell-kaje-pan (kaje with a french j) and a silent "ts" at the end. That makes it sound like a dessert to me :)
 
About the presumable psychoactive effects of calcitonin gene-related peptide:

I think there are none. neither for agonist nor for antagonists. The confusion maybe stems from the following observation:

"Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling."
Hiley C Robin; Ford William R
Biological Reviews of the Cambridge Philosophical Society 2004, 79(1), p.187

Abstract

Cannabinoids include not only plant-derived compounds (of which delta9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2-arachidonoylethanolamide) and 2-arachidonoylglycerol. Cannabinoids act on specific, G-protein-coupled, receptors which are currently divided into two types, CB1 and CB2. Relatively selective agonists and antagonists for these receptors have been developed, although one agent (SR141716A) widely used as an antagonist at CB1 receptors has non-cannabinoid receptor-mediated effects at concentrations which are often used to define the presence of the CB1 receptor. Both cannabinoid receptors are primarily coupled to Gi/o proteins and act to inhibit adenylyl cyclase. Stimulation of CB1 receptors also modulates the activity of K+ and Ca2+ channels and of protein kinase pathways including protein kinase B (Akt) which might mediate effects on apoptosis. CB, receptors may activate the extracellular signal-regulated kinase cascade through ceramide signalling. Cannabinoid actions on the cardiovascular system have been widely interpreted as being mediated by CB1 receptors although there are a growing number of observations, particularly in isolated heart and blood vessel preparations, that suggest that other cannabinoid receptors may exist. Interestingly, the currently identified cannabinoid receptors appear to be related to a wider family of lipid receptor, those for the lysophospholipids, which are also linked to Gi/o protein signalling. Anandamide also activates vanilloid VR1 receptors on sensory nerves and releases the vasoactive peptide, calcitonin gene-related peptide (CGRP), which brings about vasodilatation through its action on CGRP receptors. Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction. Therefore, their cardiovascular effects and the receptors mediating them are the subject of increasing investigative interest.

Peace! - Murphy
 
Top